Forma Therapeutics, a Phase 1 biotech developing therapies for SCD and hematologic diseases, raised $278 million in an upsized IPO by offering 13.9 million shares at $20, well above the range of $16 to $18. The company originally planned to offer 11.8 million shares. Forma Therapeutics plans to list on the Nasdaq under the symbol FMTX. Jefferies, SVB Leerink and Credit Suisse acted as lead managers on the deal.
